A retrospective 9-year cohort study was conducted to identify the hospitalization costs, length of hospital stay, and mortality associated with nephrotoxicity (NT) among 494 inpatients who were treated with conventional amphotericin B (CAB). Survival regression methods were used to model the effect of NT. The rate of NT was 12%; the overall in-hospital mortality rate was 22%. After adjustment for confounding, NT was associated with a 2.7-fold higher risk of death ( ). Although the unadjusted effects of NT on length of hospital P ! .001 stay and hospitalization costs after the initiation of CAB were consistent with small increases, such effects were not significant in multivariate models (time ratio, 1.2 [ ]; cost ratio, 1.1 [ ]). The greater the P p .2 P p .8 number of days before the onset of NT that were included in the analysis, the greater the apparent effect of NT on costs. CAB-associated NT was associated with increased mortality, but it did not impact the costs and length of hospital stay.
tify the impact of drug-related adverse events. Methodological approaches to minimize bias in the design and analysis of these types of studies have heretofore received relatively little attention.
Conventional amphotericin B (CAB) deoxycholate is an antifungal agent associated with a significant number of toxic side effects, one of the most important of which is nephrotoxicity (NT). Unfortunately, there is limited understanding of the clinical and economic impact of CAB-induced NT, although recent studies have attempted to examine this question [3] [4] [5] . In the present study, we evaluated the occurrence of NT in a large cohort of hospitalized individuals treated with varying doses of CAB to determine whether patients who had CAB-associated NT had differences in length of hospital stay, costs of hospitalization, and mortality rates when compared with patients who did not have NT. By use of survival regression methods to assess all 3 outcomes of interest, we attempted to control for confounding by use of time-varying covariables to adjust for the interval between commencement of CAB therapy and the onset of NT.
METHODS
Hospital setting, study population, and data collection. LDS Hospital is a private, 520-bed hospital located in Salt Lake City and is a teaching affiliate of the University of Utah School of Medicine. It has ∼23,000 admissions per year. The hospital has a large oncology service and includes an allogeneic bone marrow transplantation unit. The study population consisted of all adult inpatients admitted to the hospital during the period of January 1990 through September 1998 who received у2 doses of CAB.
With the help of computerized hospital files, we identified study subjects from the population of all inpatients. Data were extracted from administration, pharmacy, and laboratory databases and were compiled into a single data set by means of a database management system that has been described elsewhere [6] .
Definitions and study design. Use of CAB formed the primary time axis. We recorded the numbers of daily, cumulative, and total CAB doses [7] . Serial serum creatinine levels during therapy with CAB were compared with the baseline creatinine level to assess the occurrence of NT. The effects of CAB-induced elevation of the creatinine level on mortality, length of hospital stay, and daily costs of hospitalization were examined in 2 ways: first, by including serum creatinine level as a continuous variable, and second, by defining the occurrence of NT as a discrete event. The criterion for NT in this analysis was doubling of the serum creatinine level during CAB therapy from baseline up to an absolute value of у2.0 mg/dL [5, 7, 8] . The baseline creatinine value was defined as the mean of the serum creatinine measurements during the 3-day interval before the initiation of CAB therapy.
Three outcomes were examined: in-hospital mortality rate, length of hospital stay, and daily hospitalization costs after the initiation of CAB therapy. All patients were observed until discharge from the hospital or in-hospital death. Length of hospital stay was calculated as the number of days in the hospital. Costs were extracted from the hospital's cost accounting program, the Standard Cost Manager, which is a transaction-based microcosting system. This system identifies and aggregates the variable-and fixed-cost components of patient activities, hospital services, and products according to the date of service [1] . The daily costs of hospitalization were studied only for patients admitted after 1 January 1993, because such data were not available before this date. Costs were computed in 1998 US dollars by applying a yearly consumer price index for hospital services [9] .
The demographic and clinical variables that we studied as potential risk factors for mortality or increased length of hospital stay were age, sex, race, body weight, baseline creatinine level, medical or surgical status, primary diagnosis, chronic comorbid conditions, type of infection, transplantation status, severity of illness (defined by daily nursing acuity scores, which were determined by nurse responses to standardized questions about the care of the patient, representing an index of the time required for each activity), treatment in the intensive care unit, and CAB-associated NT [7] .
Statistical analysis. We expressed continuous variables as the or, if the distribution was skewed, as the memean ‫ע‬ SD dian and interquartile range. Survival analytic methods were used to model the effect of NT on length of hospital stay, costs, and mortality rate after the initiation of CAB therapy. For all analyses, time 0 was considered to be the day of initiation of CAB therapy.
The use of survival analysis to analyze the impact of inhospital events, such as NT, offered the following advantages: (1) on each day after the initiation of CAB therapy, patients with NT were compared with patients who were still receiving CAB and who had not experienced NT; (2) the relationship between change in kidney function and outcome could also be assessed by modeling the serum creatinine level as a continuous variable; (3) we could account for confounding factors in multivariable models with time-dependent covariates [10] ; and (4) for analyses of length of hospital stay and costs of hospitalization, patients who died were treated as "censored"-that is, for a patient who died, the full length of time for recovery to the point of discharge from the hospital was considered unknown. Alternative analyses that excluded patients who died were performed and yielded effect estimates similar to the main results.
For the mortality analysis, we used Cox proportional hazard regression. Patients were censored on the day of discharge from the hospital. The effect of NT on mortality was expressed as a hazard ratio (HR). Proportional hazard assumptions were examined by graphical analysis and by testing the null hypothesis that the slope of the Schoenfeld residuals was zero [11] . For continuous variables, the linearity of effect was tested by plotting b coefficients against grouped levels of the covariate and by obtaining smoothed plots of the martingale residuals [12] .
An accelerated failure time model (Weibull model) was used to analyze the length of hospital stay after it was determined that the distributional fit was adequate. The Weibull model was parameterized in the form of logarithmic time, so that the exponentiated coefficients could be interpreted as multiplicative effects on length of hospital stay or time ratios [13] .
We also applied a parametric survival model to the cost analysis [14, 15] ; a log-normal distribution was specified on the basis of adequacy of fit. When survival analysis is applied to cost studies, cost replaces time as the dependent variable [16] . Costs accumulate on each day of hospitalization, allowing inclusion of such covariates as NT at the appropriate interval after initiation of CAB therapy. By use of a parametric survival model, the effect of NT could be expressed as a cost ratio. For control of confounding, diagnosis-related groups (DRGs) were stratified into 4 cost levels on the basis of mean costs for each DRG within the study population. The DRG cost level was then included in multivariable models as a covariate. To explain the observed differences between our cost estimates and those of previous reports, we conducted an additional analysis to examine the following question: are there changes in the final cost model if the effect of NT is assumed to begin before it is actually detected?
As stated above, NT was incorporated as a time-dependent covariate in all survival models so that comparisons between patients who had and patients who did not have NT were made at comparable intervals from initiation of CAB therapy [10, 17, 18] . Variables with on univariable analyses were can-P р .20 didates for multivariable analysis, as was the main variable of interest (NT). Variables were also tested for confounding by adding them one at a time to a model and examining their effects on the b coefficients of the main exposure variable. Those variables that caused substantial confounding (change in b coefficient of 120%) were kept in the final model. We tested for pairwise interactions between important risk factors in the multivariable models by use of appropriate multiplicative terms. These statistics were calculated by use of STATA software, version 6.0 (STATA). All statistical tests were 2 tailed. P ! .05 was considered to be significant.
Finally, to corroborate the findings of the parametric survival model, mixed regression methods for longitudinal data were used to estimate the effect of NT on costs of hospitalization. Random effects were specified for the intercept term and slope, represented by days receiving CAB. Within-subject variance was fit with an unstructured correlation structure. Fixed variables that were included in this model were age, length of hospital stay, and severity of illness, expressed as year-specific DRG cost weights [5] . We used the PROC MIXED function in SAS software, version 7.0 (SAS Institute), for this analysis.
RESULTS
A total of 494 patients were included in the study. The majority of patients (361 [73%]) received CAB for empirical treatment. Important patient characteristics are shown in table 1. Overall, 58 patients (12%) had NT. Initiation of hemodialysis was causally related to CAB therapy in 3 patients.
Mortality. One hundred eleven (22%) of the 494 patients died in the hospital. Figure 1 illustrates the cumulative probability of survival according to the occurrence of NT. According to univariable Cox analysis, patients who experienced NT had a 2.5-fold increased hazard of death (95% CI, 1.6-4.0). Table  2 summarizes the results of the univariable analysis for the association of different patient characteristics with mortality, and it lists the results of the multivariable Cox model constructed to control for confounding. Factors that were independently associated with mortality ( for all predictors) P р .01 were age of у65 years, elevated baseline creatinine level, chronic renal impairment, liver disease, increased acuity score, receipt of mechanical ventilation for 124 h, and aspergillosis (table 2). After adjustment for confounding, NT was associated with a 2.7-fold higher hazard of death ( ). Models that included P ! .001 serum creatinine level as a continuous variable demonstrated a highly linear relationship between serum creatinine level during CAB therapy and hazard of mortality (adjusted HR, 1.4; 95% CI, 1.3-1.6).
Length of hospital stay. The median time interval from initiation of CAB therapy to discharge from the hospital was 19 days (interquartile range, 8-36) for patients without renal toxicity and 23 days (interquartile range, 17-45) for those ex- periencing NT. The median length of hospital stay for the latter group was 9 days from initiation of CAB therapy to the occurrence of NT and 14 days from NT to discharge. Figure 2 demonstrates the probability of discharge after initiation of CAB therapy, according to the presence or absence of NT. On univariate analysis, a trend toward increased length of hospital stay was observed in patients who experienced NT (time ratio, 1.2;
), which was most pronounced early after the com-P p .3 mencement of CAB therapy. Adjustment for important confounding factors, such as the nurse acuity score, did not significantly change the time ratio (1.2; 95% CI, 0.9-1.6; ). P p .2 When examined in the model as a continuous variable, increases in the serum creatinine level also were not significantly associated with increased length of hospital stay after adjustment for illness acuity (time ratio, 1.0; 95% CI, 0.9-1.1; P p ). In contrast, a longer duration of hospital stay was observed .8 for patients who had undergone surgery (time ratio, 1.4; 95% CI, 1.2-1.7;
), who had leukemia (time ratio, 1.3; 95% P ! .001 CI, 1.1-1.6; ), or who had an elevated acuity score (time P p .01 ratio per 1-point increase, 1.03; 95% CI, 1.02-1.04;
).
The results were not affected by the choice of the survival model-that is, when a Cox proportional hazard model was applied, the association between NT and length of hospital stay remained statistically nonsignificant (HR, 0.8; 95% CI, 0.5-1.1;
). P p .2
Hospital costs. Daily costs of hospitalization were available for 292 patients admitted after 1 January 1993; 30 (10%) of these patients developed NT. Fourteen of these 30 patients died. The mean total costs per admission were $58,861 for patients who experienced NT and $44,314 for those without renal toxicity. For patients with NT, the mean hospital costs were $28,695 before and $30,166 after the onset of NT. The mean intensive care unit cost was $16,825, and the mean pharmacy cost was $11,017.
The univariate cost ratio associated with NT was 0.7 (95% CI, 0.3-1.8; ). After adjustment for different DRG-cost P p .5 quartiles, renal toxicity still was not associated with significantly increased costs of hospitalization (cost ratio, 1.1; 95% CI, 0.7-1.8;
). Models that used DRG cost weights instead P p .8 of DRG cost quartiles produced comparable results (adjusted cost ratio, 0.9;
). Exclusion of all 68 patients (23%) who P p .8 died in the hospital rather than treatment of these patients as censored did not affect the results (adjusted cost ratio, 0.75;
). P p . 3 When the serum creatinine level during CAB therapy was examined as a continuous variable, a statistically significant effect was seen on univariate analysis (cost ratio, 1.3; ), P p .01 but not after adjusting for baseline creatinine level and DRGcost group (cost ratio, 1.1;
). The results were not ma-P p .5 terially affected by the choice of the model form: a statistically significant effect of NT also was not observed when Cox proportional hazard regression was used instead of the log-normal parametric model. In addition, mixed-effect regression models were created to evaluate the association between NT and daily costs. After adjustment for days in the hospital, DRG weight, and age, NT was associated with a $40 increase in per-day costs, an effect that was not significant ( ). P p .8 Finally, by use of the survival model, we assessed the magnitude by which the results would be affected if costs that occurred before the calculated onset of NT were included in the analysis. As shown in figure 3 , this analysis revealed that the greater the number of days before the calculated onset of CAB-associated NT that were included in the analysis, the greater the apparent effect of NT on costs. For instance, the estimated effect of CAB-associated NT on costs became statistically significant (cost ratio, 1.6; ) when the costs that P p .02 occurred within 7 days before the calculated onset of NT were included in the analysis.
DISCUSSION
In this retrospective cohort study, we examined clinical and economic outcomes associated with renal toxicity related to receipt of CAB therapy. As described elsewhere [13] , the use of survival methods in our analyses ensured that the effect of NT was always examined relative to other patients who were still hospitalized for the same follow-up period.
The principal findings of this study, which was performed with a heterogeneous patient population, are as follows: (1) NT occurred in 58 patients (12%) and was associated with a 2.7-fold higher mortality rate after controlling for underlying disease and severity of illness; (2) although the unadjusted effects of NT on length of hospital stay and hospitalization costs after the initiation of CAB were consistent with small to moderate increases, such effects were not significant in multivariate models that accounted for the interval between the commencement of CAB therapy and the onset of NT (time ratio, 1. 2  [ ]; cost ratio, 1.1 [ ]); and (3) the greater the num-P p .2 P p .8 ber of days before the calculated onset of CAB-associated NT that were included in the cost analysis, the greater the apparent effect of NT on costs. Thus, this study demonstrates the danger of violating basic cause-effect relations in cost analysis by attributing costs to an adverse event before the event occurs.
The results of our study extend those of previous studies about the association between medically induced renal toxicity and mortality [19] [20] [21] . The administration of nephrotoxic agents especially can result in an acute reduction in renal function and can ultimately cause the death of a patient [22] . Wingard et al. [3] also reported an increased mortality rate associated with the toxic renal damage induced by CAB use. In particular, hemodialysis may have contributed to the observed increase in the mortality rate. However, these authors and others cautioned that the increased mortality rate among inpatients who develop acute renal failure may be determined by preexisting comorbid conditions that also predispose patients to acute renal failure and by simultaneous, nonrenal complications, which are usually related to multiple organ dysfunction [21] . An alternative interpretation of the increased mortality rate could be that some patients with NT were receiving inadequate antifungal therapy as a consequence of a dose reduction in response to NT. Although the evidence of a statistical association between CAB-induced NT and mortality does not prove causality, our multivariable analysis suggests that the association between renal toxicity and mortality cannot be attributed to comorbidities or severity of illness alone.
Our finding that NT was not significantly associated with an increased length of hospital stay and costs of hospitalization stands in contrast to other studies that found that CABassociated renal toxicity increases costs [4, 5] . Cagnoni et al. [4] , for example, calculated that the hospital costs were sig- Figure 2 . Kaplan-Meier curve for the probability of patients being discharged from the hospital, stratified by the occurrence of nephrotoxicity. The graphic representation shows the proportion of patients who are discharged from the hospital at a given time.
nificantly greater for patients who developed NT compared with those who did not ($59,621 vs. $34,415;
), al-P ! .001 though CAB-treated patients had lower mean hospitalization costs after treatment ($43,183) than did patients treated with lipid formulations of amphotericin B ($48,962). In the context of other work on the subject, the results of a single observational study such as ours need to be interpreted with caution. For instance, the 95% CIs around the effect estimates in our analysis are still compatible with small to moderate effects of NT on costs and length of hospital stay. Yet it is important to consider methodological differences among studies that have attempted to estimate the attributable effect of adverse events, which may occur at various intervals after starting use of a medication. In their comparative analyses, previous studies have included length of stay and costs of hospitalization for patients with NT that were incurred before renal toxicity may have actually occurred [4, 5] . Adjustment for severity of illness does not adequately control for confounding due to the length of time from initiation of therapy to the occurrence of toxicity. Even patients with the same severity of illness experience a distribution of different time intervals to the adverse event; thus, patients with NT or another drug-related adverse event may have longer total lengths of hospital stay, independent of any effect of toxicity. In our analysis of costs that tested different assumptions, we showed that the greater the number of CABtreatment days before the calculated occurrence of NT that are included, the greater the apparent effect of NT on total costs. Thus, estimation of cost effects may often be overestimated if the interval to onset of renal toxicity is not properly accounted for in the analysis.
The strengths of our study were the large sample size of our patient population and the use of analytic methods that allow for time-dependent covariates to adjust for the time interval between commencement of CAB therapy and the calculated onset of NT. Nonetheless, our study had limitations, one of which was that the cost data were not available for patients admitted to the hospital before 1993. Second, the high mortality rate among patients with NT represented a further constraint on the sample size of patients for whom costs were measurable to the point of recovery sufficient for hospital discharge. Third, our data were generated for a single tertiary care hospital; therefore, results may not be generalizable to other settings. Fourth, we cannot exclude the possibility that residual, unmeasured confounding accounted for effects noted in the study. Fifth, it is possible that NT leads to increased length of hospital stay and costs only in the subset of patients with severe renal dysfunction and great variation in serum creatinine levels, a group of patients that may have been of insufficient size in this study to observe an impact. It is also possible that a cost effect of NT may be difficult to detect in patients whose length of hospital stay is expected to be prolonged regardless of individual drug-related toxicities, as a result of the need for chemotherapy or treatment of their underlying diseases.
NT is just one of the adverse consequences of CAB use. In future studies, an analysis of outcomes associated with the full spectrum of CAB-induced toxicities is warranted. Addi- tional research on the optimal statistical methods for assessing the impact of drug-related adverse events is also needed. In particular, the issue of use of time-dependent survival methods when the censoring mechanism is not external to the failure process needs to be addressed. If there are incomplete follow-up data, standard survival analysis techniques may be inappropriate to estimate medical costs or length of stay [23] . However, previous work has demonstrated that modified time-to-event methodology may be applied for this type of outcome analysis, especially when cost data are available per day of hospitalization [14, 24, 25] . Finally, as additional antifungal agents become available for use and because different options exist for combination therapy, the evaluation of competing therapeutic strategies and associated risks becomes even more complex.
In summary, our data expand the idea that CAB-induced renal toxicity is associated with increased mortality rates. Serum creatinine levels during CAB therapy modeled as a continuous variable were also associated with increased mortality rates. The unadjusted effects of NT after the initiation of CAB therapy were consistent with small to moderate increases in length of hospital stay and costs of hospitalization. Such effects were not significant in multivariate models that accounted for the interval between the start of CAB therapy and the calculated onset of NT (time ratio, 1.2 [ ]; cost ratio, 1.1 [ ]), al-P p .2 P p .8 though they were significant in specifications that did not account for this difference (cost ratio, 1.6;
). Estimation P p .02 of cost effects of adverse events may be overestimated if one does not properly account for the interval to occurrence and the duration of the adverse event in the statistical analysis.
